Actively Recruiting
Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes
Led by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Updated on 2026-02-02
250
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating myocardial perfusion abnormalities using cardiac magnetic resonance (CMR) perfusion imaging in patients with hypertrophic cardiomyopathy (HCM) types, including sarcomeric and non-sarcomeric HCM, Anderson-Fabry disease, and cardiac amyloidosis. The study also includes first-degree relatives of affected patients and genetic mutation carriers. By comparing blood flow and perfusion patterns, the study aims to identify distinctive signs that may improve diagnosis, risk assessment, and understanding of ischemia's role in disease progression and outcomes. This observational study involves imaging participants' hearts with CMR to assess myocardial perfusion. Participants include those diagnosed with hypertrophic cardiomyopathy or related genetic conditions, their close relatives, and genetic mutation carriers. The study will analyze quantitative and qualitative perfusion defects at the start and again after 36 months to observe changes over time. Participants will undergo cardiac magnetic resonance imaging at baseline and after 36 months. Researchers will measure and compare perfusion defects using both quantitative and qualitative methods. The study focuses on gathering detailed imaging data to understand myocardial blood flow differences among the various cardiomyopathy types and genetic profiles. The total participation time involves these two main imaging timepoints, with ongoing observation to support long-term insights.
CONDITIONS
Brief Title
Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Confirmed diagnosis of hypertrophic cardiomyopathy or related phenotype according to current ESC guidelines, or first-degree relative of such a patient, or genetic mutation carrier for hypertrophic cardiomyopathy
- Indication to undergo cardiac magnetic resonance imaging (CMR) according to current ESC guidelines
- Age 18 years or older
- Written informed consent obtained
You will not qualify if you...
- History of previous myocardial infarction or myocardial revascularization (coronary artery bypass grafting or percutaneous coronary angioplasty)
- Evidence of coronary artery stenosis 50% or greater on coronary CT scan or invasive coronary angiography
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Baseline and after 36 months
Participants undergo cardiac magnetic resonance imaging (CMR) to assess myocardial perfusion and characterize hypertrophic cardiomyopathy phenotypes.
2 visits (in-person)
Duration - 36 months
Participants are monitored over time to evaluate changes in myocardial perfusion and disease progression.
Follow-up visit after 36 months
Trial Site Locations
Total: 1 location
1
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, BO, Italy, 40124
Actively Recruiting
Research Team
L
Luigi Lovato
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here